A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations.
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Jun 2011 Study design details presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2011 New trial record